The outsiders: Emerging roles of ectonucleotidases in inflammation

Science Translational Medicine

Volumn 4, Issue 146, 2012, Pages

  Szabo, Csaba ^a   Pacher, Pal ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (CYCLOHEXYLETHYLTHIO)ADENOSINE 5' MONOPHOSPHATE; 5' NUCLEOTIDASE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE DEAMINASE; ADENOSINE PHOSPHATE; APYRASE; CD39 ANTIGEN; ECTONUCLEOTIDASE; IMMUNOSUPPRESSIVE AGENT; NUCLEOTIDASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; DRUG EFFECT; ENZYME DEGRADATION; ENZYME PRODRUG THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTRACELLULAR TRANSPORT; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; VASCULITIS;

5'-NUCLEOTIDASE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; ARTHRITIS, RHEUMATOID; INFLAMMATION; JOINTS; MALE; PRODRUGS; RECEPTOR, ADENOSINE A2A;

EID: 84864880288     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004378     Document Type: Review

References (31)

1. A. N. Drury, A. Szent-Györgyi, The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. 68, 213-237 (1929).
2. T. De Gubareff, W. Sleator Jr., Effect of caffeine on mammalian atrial muscle, and its interaction with adenosine and calcium. J. Pharmacol. Exp. Ther. 148, 202-214 (1965).
3. G. Haskó, J. Linden, B. Cronstein, P. Pacher, Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759-770 (2008).
4. C. E. Müller, K. A. Jacobson, Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808, 12903-1308 (2011).
5. G. Hasko, B. Cronstein, C. Szabo, Eds., Adenosine and Adenosine Receptors in Inflammation and Immunity (CRC Press, Boca Raton, FL, 2006).
6. J. Linden, K. A. Jacobson, Eds., Pharmacology of Purine and Pyrimidine Receptors (Elsevier, Amsterdam, Netherlands, 2011).
7. G. Vassort, Adenosine 5′-triphosphate: A P2-purinergic agonist in the myocardium. Physiol. Rev. 81, 767-806 (2001).
8. U. Flögel, S. Burghoff, P. L. E. M. van Lent, S. Temme, L. Galbarz, Z. Ding, A. El-Tayeb, S. Huels, F. Bönner, N. Borg, C. Jacoby, C. E. Müller, W. B. van den Berg, J. Schrader, Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 4, 146ra108 (2012).
9. N. A. Louis, A. M. Robinson, C. F. MacManus, J. Karhausen, M. Scully, S. P. Colgan, Control of IFN-alphaA by CD73: Implications for mucosal inflammation. J. Immunol. 180, 4246-4255 (2008).
10. T. Eckle, L. Füllbier, M. Wehrmann, J. Khoury, M. Mittelbronn, J. Ibla, P. Rosenberger, H. K. Eltzschig, Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J. Immunol. 178, 8127-8137 (2007).
11. J. Reutershan, I. Vollmer, S. Stark, R. Wagner, K. C. Ngamsri, H. K. Eltzschig, Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 23, 473-482 (2009).
12. A. Buchheiser, A. Ebner, S. Burghoff, Z. Ding, M. Romio, C. Viethen, A. Lindecke, K. Köhrer, J. W. Fischer, J. Schrader, Inactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice. Cardiovasc. Res. 92, 338-347 (2011).
13. P. Koszalka, B. Ozüyaman, Y. Huo, A. Zernecke, U. Flögel, N. Braun, A. Buchheiser, U. K. M. Decking, M. L. Smith, J. Sévigny, A. Gear, A. A. Weber, A. Molojavyi, Z. Ding, C. Weber, K. Ley, H. Zimmermann, A. Gödecke, J. Schrader, Targeted disruption of cd73/ecto-5′- nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 95, 814-821 (2004).
14. A. Zernecke, K. Bidzhekov, B. Ozüyaman, L. Fraemohs, E. A. Liehn, J. M. Lüscher-Firzlaff, B. Lüscher, J. Schrader, C. Weber, CD73/ecto-5′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 113, 2120-2127 (2006).
15. T. Ohtsuka, P. S. Changelian, D. Bouïs, K. Noon, H. Harada, V. N. Lama, D. J. Pinsky, Ecto-5′-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J. Immunol. 185, 1321-1329 (2010).
16. H. Tsukamoto, P. Chernogorova, K. Ayata, U. V. Gerlach, A. Rughani, J. W. Ritchey, J. Ganesan, M. Follo, R. Zeiser, L. F. Thompson, M. Idzko, Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood 119, 4554-4564 (2012).
17. M. C. Montesinos, M. Takedachi, L. F. Thompson, T. F. Wilder, P. Fernández, B. N. Cronstein, The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: Findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum. 56, 1440-1445 (2007).
18. N. A. Sowa, B. Taylor-Blake, M. J. Zylka, Ecto-5′-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits. J. Neurosci. 30, 2235-2244 (2010).
19. G. Haskó, B. Csóka, B. Koscsó, R. Chandra, P. Pacher, L. F. Thompson, E. A. Deitch, Z. Spolarics, L. Virág, P. Gergely, R. H. Rolandelli, Z. H. Németh, Ecto-5′-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J. Immunol. 187, 4256-4267 (2011).
20. C. Blume, A. Felix, N. Shushakova, F. Gueler, C. S. Falk, H. Haller, J. Schrader, Autoimmunity in CD73/ecto-5′-nucleotidase deficient mice induces renal injury. PLoS ONE 7, e37100 (2012).
21. J. B. Volmer, L. F. Thompson, M. R. Blackburn, Ecto-5′-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J. Immunol. 176, 4449-4458 (2006).
22. R. Resta, Y. Yamashita, L. F. Thompson, Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161, 95-109 (1998).
23. P. A. Beavis, J. Stagg, P. K. Darcy, M. J. Smyth, CD73: A potent suppressor of antitumor immune responses. Trends Immunol. 33, 231-237 (2012).
24. S. Jalkanen, M. Salmi, VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler. Thromb. Vasc. Biol. 28, 18-26 (2008).
25. Y. Zhou, J. N. Murthy, D. Zeng, L. Belardinelli, M. R. Blackburn, Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS ONE 5, e9224 (2010).
26. B. Zhang, CD73: A novel target for cancer immunotherapy. Cancer Res. 70, 6407-6411 (2010).
27. L. Morabito, M. C. Montesinos, D. M. Schreibman, L. Balter, L. F. Thompson, R. Resta, G. Carlin, M. A. Huie, B. N. Cronstein, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101, 295-300 (1998).
28. P. Meijer, W. J. G. Oyen, D. Dekker, P. H. H. van den Broek, C. W. Wouters, O. C. Boerman, G. J. Scheff er, P. Smits, G. A. Rongen, Rosuvastatin increases extracellular adenosine formation in humans in vivo: A new perspective on cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 29, 963-968 (2009).
29. J. Niemelä, T. Henttinen, G. G. Yegutkin, L. Airas, A. M. Kujari, P. Rajala, S. Jalkanen, IFN-alpha induced adenosine production on the endothelium: A mechanism mediated by CD73 (ecto-5′-nucleotidase) up-regulation. J. Immunol. 172, 1646-1653 (2004).
30. J. Kiss, G. G. Yegutkin, K. Koskinen, T. Savunen, S. Jalkanen, M. Salmi, IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 37, 3334-3338 (2007).
31. H. Moncrieffe, K. Nistala, Y. Kamhieh, J. Evans, A. Eddaoudi, S. Eaton, L. R. Wedderburn, High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J. Immunol. 185, 134-143 (2010).